<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446966</url>
  </required_header>
  <id_info>
    <org_study_id>1733860001</org_study_id>
    <nct_id>NCT00446966</nct_id>
  </id_info>
  <brief_title>Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery</brief_title>
  <acronym>FISH</acronym>
  <official_title>Fish Oil to Inhibit Supraventricular Arrhythmias After Cardiac Surgery: The Fish Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chirag Sandesara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine if omega-3 polyunsaturated fatty acids
      reduce atrial fibrillation and other outcomes after cardiac surgery. In this
      placebo-controlled trial, patients undergoing elective coronary artery bypass graft surgery
      with or without valve repair will be treated with omega-3 polyunsaturated fatty acids
      perioperatively. The following hypotheses will be tested: 1. omega-3 polyunsaturated fatty
      acids reduces the incidence of atrial fibrillation (AF) after cardiac surgery, 2. omega-3
      polyunsaturated fatty acids, administered in the perioperative period for cardiac surgery,
      decreases postoperative complication rates, and 3. omega-3 polyunsaturated fatty acids
      decrease intensive care unit and hospital length-of-stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is the most common complication after bypass surgery. It is a significant
      burden to the healthcare system because it is associated with increased hospital costs and a
      longer hospital length-of-stay. Atrial fibrillation occurring after bypass surgery is
      associated with increased morbidity and mortality. Atrial fibrillation is also associated
      with an increased risk for strokes, use of potentially harmful drugs, and the need for
      pacemaker therapy.

      This study is for patients who are undergoing elective bypass surgery. Patients who meet
      study criteria and who consent to participate in the study will be randomized to treatment
      with omega-3 fatty acids or matching corn oil placebo, prior to surgery. After surgery,
      treatment will continue until the primary endpoint, atrial fibrillation, is reached, or 14
      days, whichever is first.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Developed Postoperative Atrial Fibrillation</measure>
    <time_frame>14 days</time_frame>
    <description>The primary outcome in this study is post-bypass atrial fibrillation documented by ECG or rhythm strip and requiring treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>fish oil , corn oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highly purified pharmaceutical grade omega three polyunsaturated fatty acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>olive oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega Three Polyunsaturated fatty acids</intervention_name>
    <description>2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.</description>
    <arm_group_label>fish oil , corn oil</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Lovaza, Omega three polyunsaturate ethyl esters</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-85 years old.

          -  Elective coronary artery bypass (CABG) operation with or without concomitant valve
             surgery planned for at least 2 days after enrollment.

          -  Signed, documented informed consent prior to admission to the study.

        Exclusion Criteria:

          -  Urgent or emergent bypass required to be performed &lt;24 hrs after screening.

          -  Unstable angina, requiring intervention or CABG &lt;24 hrs after screening.

          -  Decompensated congestive heart failure.

          -  Chronic, persistent atrial fibrillation - patient in atrial fibrillation at the time
             of screening or enrollment or scheduled for a maze procedure or pulmonary vein
             isolation at the time of surgery.

          -  Known sensitivity to Omacor (0mega-3 acid ethyl esters) and hypersensitivity to fish,
             fish products or corn oil.

          -  Patients requiring warfarin or Lovenox the 2 days prior to bypass surgery.

          -  Patients on Class I or III antiarrhythmic agents (quinidine, procainamide,
             disopyramide, flecainide, propafenone, moricizine, dofetilide, sotalol, amiodarone) or
             who have taken these drugs within 5 elimination half-lives of the drug (or within 2
             months for amiodarone).

          -  Patients who are pregnant or nursing.

          -  Patients unable to provide/sign informed consent.

          -  Patients currently enrolled in another clinical trial without a 30 day washout period.

          -  Patients currently taking marine based omega-three fish oil supplements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chirag M Sandesara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Virginia Cardiovascular Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <results_first_submitted>January 22, 2012</results_first_submitted>
  <results_first_submitted_qc>September 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2018</results_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Chirag Sandesara</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>coronary artery disease bypass graft surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from February 2007 to December 2009. Patients were recruited from cardiothoracic clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fish Oil</title>
          <description>Highly purified pharmaceutical grade omega three polyunsaturated fatty acids</description>
        </group>
        <group group_id="P2">
          <title>Corn Oil</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fish Oil</title>
          <description>Highly purified pharmaceutical grade omega three polyunsaturated fatty acids</description>
        </group>
        <group group_id="B2">
          <title>Corn Oil</title>
          <description>Standard grade corn oil</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="9.5"/>
                    <measurement group_id="B2" value="62" spread="11.4"/>
                    <measurement group_id="B3" value="62" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Postoperative Atrial Fibrillation</title>
        <description>The primary outcome in this study is post-bypass atrial fibrillation documented by ECG or rhythm strip and requiring treatment.</description>
        <time_frame>14 days</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Corn Oil</title>
            <description>Corn oil</description>
          </group>
          <group group_id="O2">
            <title>Fish Oil</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Postoperative Atrial Fibrillation</title>
          <description>The primary outcome in this study is post-bypass atrial fibrillation documented by ECG or rhythm strip and requiring treatment.</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fish Oil</title>
          <description>Highly purified pharmaceutical grade omega three polyunsaturated fatty acids</description>
        </group>
        <group group_id="E2">
          <title>Corn Oil</title>
          <description>Standard corn oil</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Chirag Sandesara</name_or_title>
      <organization>Carient Heart and Vascular</organization>
      <phone>7033358750</phone>
      <email>csandesara@carient.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

